Arina V Zinkina-Orikhan, PhD
Director of Clinical Development Department, BIOCAD
6
0
0
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
emilie garrido pradalie
APHM
Shared therapeutic areas:
Waqar ahmed awan, Phd
Riphah International University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Ahmed Elshafeey, Ph.D. Pharma
Genuine Research Center
Shared therapeutic areas:
Suman Wason, MD
Lexicon Pharmaceuticals, Inc.
Shared therapeutic areas:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Urielle Desalbres
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Dorian Williams, M.D.
Kendle International Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects
A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
All 6 trials loaded